Digoxin: Atomic Insights for Cardiac and Antiviral Research

Executive Summary: Digoxin is a potent cardiac glycoside that inhibits the Na+/K+-ATPase pump, increasing intracellular sodium and calcium, thereby enhancing cardiac contractility (https://www.apexbt.com/digoxin.html). It is widely used in research on heart failure, arrhythmias, and has demonstrated dose-dependent antiviral activity against chikungunya virus (CHIKV) in multiple human and animal cell lines at 0.01–10 μM concentrations (https://doi.org/10.1016/j.biopha.2025.118665). The compound is highly soluble in DMSO (≥33.25 mg/mL), insoluble in water and ethanol, and is supplied at >98.6% purity. Intravenous administration in canine heart failure models (1–1.2 mg) improves cardiac output and decreases right atrial pressure. Digoxin from APExBIO includes HPLC, NMR, and MSDS documentation for reproducibility and quality control (APExBIO).

Biological Rationale

Digoxin is a canonical cardiac glycoside isolated from Digitalis lanata. Its primary research applications include modulation of cardiac contractility, evaluation of anti-arrhythmic properties, and mechanistic studies in heart failure. The Na+/K+-ATPase pump is a ubiquitous transmembrane enzyme responsible for maintaining sodium and potassium gradients in mammalian cells. Inhibition of this pump by Digoxin leads to downstream effects on cellular calcium, which is critical for cardiac muscle contraction. Recent evidence extends the utility of Digoxin to antiviral research, particularly as an inhibitor of chikungunya virus (CHIKV) infection in human and primate cell models (https://doi.org/10.1016/j.biopha.2025.118665). These applications underscore its dual role as both a cardiovascular modulator and an antiviral agent (related analysis—this article updates the mechanistic focus with new quantitative benchmarks).

Mechanism of Action of Digoxin

Digoxin exerts its primary effect by binding to and inhibiting the Na+/K+-ATPase pump on the plasma membrane of cardiomyocytes. This inhibition increases intracellular sodium concentration, which in turn reduces the activity of the sodium-calcium exchanger. The resulting accumulation of intracellular calcium enhances myocardial contractility (positive inotropic effect). At the molecular level, this mechanism is leveraged to study heart failure and arrhythmias by modulating contractility and conduction. Additionally, Digoxin's disruption of ionic homeostasis has been implicated in blocking the replication cycle of certain viruses, including CHIKV, in cell-based assays (https://doi.org/10.1016/j.biopha.2025.118665).

Evidence & Benchmarks

• Digoxin inhibits Na+/K+-ATPase activity in mammalian cells at nanomolar to micromolar concentrations, resulting in increased intracellular sodium and calcium (https://www.apexbt.com/digoxin.html).
• In U-2 OS, primary human synovial fibroblasts, and Vero cells, Digoxin reduces chikungunya virus (CHIKV) infection in a dose-dependent manner at 0.01–10 μM (https://doi.org/10.1016/j.biopha.2025.118665).
• In canine models of congestive heart failure, intravenous Digoxin (1–1.2 mg) increases cardiac output and decreases right atrial pressure, measured under controlled conditions (https://www.apexbt.com/digoxin.html).
• Digoxin demonstrates high solubility in DMSO (≥33.25 mg/mL) and is insoluble in water and ethanol, enabling its use in DMSO-based in vitro assays (https://www.apexbt.com/digoxin.html).
• Product purity exceeds 98.6%, validated by HPLC and NMR, with batch-specific MSDS documentation for laboratory reproducibility (https://www.apexbt.com/digoxin.html).

Applications, Limits & Misconceptions

Digoxin is widely applied in cardiac research, arrhythmia models, and as an antiviral tool in cellular assays. It is not indicated for direct clinical use in humans without regulatory approval and clinical oversight. Its efficacy and safety are established in preclinical models, not as a therapeutic for viral infections in humans. The compound’s high potency necessitates careful dose calibration in experimental workflows. This article extends prior summaries (see guide—here, we specify solubility constraints and antiviral benchmarks) and provides nuanced boundaries for translational deployment.

Common Pitfalls or Misconceptions

• Digoxin should not be used in water or ethanol-based assays due to insolubility; DMSO is the recommended solvent (https://www.apexbt.com/digoxin.html).
• Long-term storage of prepared Digoxin solutions is not advised; prepare solutions fresh for experimental use.
• Antiviral effects observed in vitro do not equate to clinical antiviral efficacy in humans.
• Misuse or overdosing can result in cytotoxicity in cell culture models; titrate concentrations carefully.
• Not all cell lines or animal models will respond identically; confirm activity in each specific experimental context (see mechanistic review—this dossier adds new cell line-specific data).

Workflow Integration & Parameters

For in vitro research, Digoxin should be dissolved in DMSO to achieve concentrations up to 33.25 mg/mL. The recommended working range for antiviral assays is 0.01–10 μM. For animal studies, validated dosing regimens include 1–1.2 mg intravenous administration in canine heart failure models. Product quality is ensured through HPLC, NMR, and MSDS batch documentation from APExBIO. Store solid Digoxin at room temperature and avoid storing prepared solutions for extended periods. For detailed troubleshooting and scenario-driven guidance, refer to the dedicated best practices article (scientific best practices—this article provides updated purity and PK context).

Conclusion & Outlook

Digoxin (SKU B7684) from APExBIO is a high-purity, validated Na+/K+-ATPase pump inhibitor for use in cardiac and antiviral research. Its dual mechanistic profile—modulating cardiac contractility and inhibiting CHIKV infection—makes it a versatile tool for translational studies. Researchers are advised to use DMSO as solvent, calibrate dosing, and consult batch QC documentation for reproducibility. Continued integration of pharmacokinetic and mechanistic insights will advance the deployment of Digoxin in both cardiovascular and virology workflows. For more information and ordering details, refer to the Digoxin product page.